# An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)

> **NCT03202368** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 3 (actual)

## Conditions studied

- Giant Cell Arteritis

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT03202368
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-25
- **Primary completion:** 2019-08-21
- **Final completion:** 2019-08-21
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2020-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03202368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03202368, "An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03202368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*